Ligand Pharmaceuticals Incorporated's ability to collect accounts receivable sequentially worsen to 4.89, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Ligand Pharmaceuticals Incorporated's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 75 days, from 70 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 383 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2463 to 2562.

What is Receivable Turnover Ratio?
What is Ligand Pharmaceuticals Incorporated Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LGND Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	62.3 %	38.69 %	55.31 %	67.73 %	10.16 %
Y / Y Revenue Change	33.73 %	14.09 %	40.01 %	122.85 %	14.68 %
Receivable Turnover Ratio (TTM)	4.89	5.18	5.45	5.71	4.92
LGND's Total Ranking	# 2562	# 2463	# 2531	# 2620	# 2606
Accounts Receivable average collection period days	75	70	67	64	74
Seq. Receivable Change	25.53 %	-10.43 %	3.55 %	39.41 %	7.26 %
Seq. Revenue Change	23.14 %	-13.31 %	-48.32 %	142.43 %	5.06 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 117
Healthcare Sector	# 384
Overall Market	# 2562

Receivable Turnover Ratio Statistics
High	Average	Low
16.27	6.65	3.26
(Mar 31 2014)		(Jun 30 2020)

LGND Company Profile • Back to LGND Efficiency Comparisons • Compare LGND Receivables Turnover Ratio to its Competitors

Financial Statements
Ligand Pharmaceuticals Incorporated's Accounts Receivable	$ 67 Millions	Visit LGND's Balance sheet
Ligand Pharmaceuticals Incorporated's Sales TTM	$ 291 Millions	Visit LGND's Income Statement
Sources of LGND's Revenues		Visit LGND's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LGND's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LGND's Growth Rates	LGND's Roa	LGND's Inventory Turnover Ratio	LGND's Dividend Comparisons
LGND's Profitability Ratios	LGND's Roi	LGND's Asset Turnover Ratio	LGND's Dividend Growth
LGND's Valuation Ratios	LGND's Roe	LGND's Financial Strength Ratios	LGND's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Teladoc Health Inc	11.88	$ 2,489.480 Millions	$ 209.556 Millions
Premier Air Charter Holdings Inc	11.72	$ 31.562 Millions	$ 2.692 Millions
Catheter Precision Inc	11.62	$ 1.915 Millions	$ 0.165 Millions
Icu Medical Inc	11.42	$ 2,159.998 Millions	$ 189.166 Millions
National Healthcare Corp	11.40	$ 1,559.020 Millions	$ 136.723 Millions
Picard Medical Inc	11.34	$ 5.983 Millions	$ 0.528 Millions
Vaso Corporation	11.31	$ 80.220 Millions	$ 7.094 Millions
Innoviva Inc	11.22	$ 420.630 Millions	$ 37.491 Millions
Lifeloc Technologies Inc	11.19	$ 9.269 Millions	$ 0.828 Millions
Veracyte Inc	11.07	$ 544.735 Millions	$ 49.194 Millions
International Stem Cell Corporation	10.91	$ 9.514 Millions	$ 0.872 Millions
Caredx Inc	10.81	$ 458.089 Millions	$ 42.359 Millions
C4 Therapeutics Inc	10.65	$ 35.039 Millions	$ 3.290 Millions
Radnet Inc	10.53	$ 2,268.932 Millions	$ 215.450 Millions
Kymera Therapeutics Inc	10.50	$ 105.000 Millions	$ 10.000 Millions
Irhythm Holdings Inc	10.42	$ 825.702 Millions	$ 79.250 Millions
Integrated Biopharma Inc	10.38	$ 42.568 Millions	$ 4.101 Millions
Viemed Healthcare Inc	10.36	$ 301.606 Millions	$ 29.102 Millions
Lensar Inc	10.33	$ 60.264 Millions	$ 5.836 Millions
Immucell Corporation	10.30	$ 29.777 Millions	$ 2.891 Millions
Addus Homecare Corp	10.25	$ 1,475.610 Millions	$ 143.923 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Biodesix Inc	10.21	$ 102.939 Millions	$ 10.081 Millions
Kestra Medical Technologies Ltd	10.00	$ 105.939 Millions	$ 10.590 Millions
United Therapeutics Corporation	9.93	$ 3,154.500 Millions	$ 317.550 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
The Oncology Institute Inc	9.66	$ 587.244 Millions	$ 60.780 Millions
Sharps Technology Inc	9.65	$ 1.960 Millions	$ 0.203 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.